Merck & Co. (MRK) : Visionary Asset Management scooped up 784 additional shares in Merck & Co. during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 14, 2016. The investment management firm now holds a total of 53,733 shares of Merck & Co. which is valued at $3,171,322.Merck & Co. makes up approximately 1.09% of Visionary Asset Management’s portfolio.
Other Hedge Funds, Including , Legacy Private Trust boosted its stake in MRK in the latest quarter, The investment management firm added 618 additional shares and now holds a total of 12,894 shares of Merck & Co. which is valued at $761,004. Merck & Co. makes up approx 0.11% of Legacy Private Trust’s portfolio.Mitchell Sinkler Starrpa reduced its stake in MRK by selling 600 shares or 2.23% in the most recent quarter. The Hedge Fund company now holds 26,337 shares of MRK which is valued at $1,568,368. Merck & Co. makes up approx 2.10% of Mitchell Sinkler Starrpa’s portfolio.Newman Dignan Sheerar reduced its stake in MRK by selling 482 shares or 0.75% in the most recent quarter. The Hedge Fund company now holds 63,924 shares of MRK which is valued at $3,793,889. Merck & Co. makes up approx 2.44% of Newman Dignan Sheerar’s portfolio.Laurel Wealth Advisors reduced its stake in MRK by selling 637 shares or 3.42% in the most recent quarter. The Hedge Fund company now holds 17,981 shares of MRK which is valued at $1,067,172. Merck & Co. makes up approx 0.52% of Laurel Wealth Advisors’s portfolio.
Merck & Co. closed down -0.61 points or -1.02% at $59.02 with 87,69,171 shares getting traded on Monday. Post opening the session at $59, the shares hit an intraday low of $58.715 and an intraday high of $59.49 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Merck & Co. reported $0.89 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on May 5, 2016. Analyst had a consensus of $0.85. The company had revenue of $9312.00 million for the quarter, compared to analysts expectations of $9445.10 million. The company’s revenue was down -1.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.85 EPS.
Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Companys Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Companys animal health products are sold to veterinarians distributors and animal producers.